A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
| 대상 질환 | Uveal Melanoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Dana-Farber Cancer Institute |
| 상태 | 조기 종료 |
| 참여자 수 | 13 명 |
| 중재(약물) | BVD-523 |
| 시작일 | 2018년 3월 26일 |
| 완료일 | 2020년 5월 5일 |
| 결과 공개일 | 2021년 11월 11일 |
요약
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Overall Response Rate
| BVD-523 | 0 percentage of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)